Modality
Multispecific
MOA
STINGag
Target
KIF18A
Pathway
Epigenetic
MG
Development Pipeline
Preclinical
~Dec 2015
→ ~Mar 2017
Phase 1
~Jun 2017
→ ~Sep 2018
Phase 2
~Dec 2018
→ ~Mar 2020
Phase 3
Jun 2020
→ Mar 2028
Phase 3Current
NCT03954173
1,663 pts·MG
2020-06→2028-03·Not yet recruiting
NCT03798964
2,538 pts·MG
2023-06→TBD·Terminated
4,201 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-03-282.0y awayPh3 Readout· MG
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P3
Not yet…
P3
Termina…
Catalysts
Ph3 Readout
2028-03-28 · 2.0y away
MG
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03954173 | Phase 3 | MG | Not yet recr... | 1663 | LiverFat |
| NCT03798964 | Phase 3 | MG | Terminated | 2538 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| RHH-5389 | Roche | Preclinical | RET | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| INC-5849 | Incyte | Phase 2 | PCSK9 | |
| Miritinib | Neurocrine | Phase 3 | TIGIT |